Replimune (REPL) Income from Continuing Operations (2017 - 2025)
Replimune's (REPL) quarterly Income from Continuing Operations came in at 70930000.0 in Q4 2025, down 6.92% year-on-year from 76202367.61 in Q4 2024, and up 13.59% quarter-over-quarter from 82083000.0 in Q3 2025.
Replimune (REPL) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Replimune has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 70930000.0 for Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 70930000.0, down 6.92% year-over-year; the trailing twelve-month figure through Dec 2025 was 314333000.0 (down 37.72% YoY), and the FY2025 annual result was 247329000.0, down 14.61% from the prior year.
- Income from Continuing Operations came in at 70930000.0 for Q4 2025 at Replimune, up from 82083000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 22090000.0 in Q1 2021 to a low of 87183000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 50337500.0 (2023), against an average of 50879600.0.
- Across the five-year window, Income from Continuing Operations advanced 11.64% in 2024 and plunged 62.13% in 2025, its largest moves.
- Replimune's Income from Continuing Operations stood at 29611000.0 in 2021, then tumbled by 34.04% to 39690000.0 in 2022, then dropped by 28.8% to 51120000.0 in 2023, then slipped by 29.77% to 66340000.0 in 2024, then retreated by 6.92% to 70930000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 70930000.0 (Q4 2025), 82083000.0 (Q3 2025), and 87183000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | -70.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -70.93 Mn |
| Sep 30, 2025 | -82.08 Mn |
| Jun 30, 2025 | -87.18 Mn |
| Mar 31, 2025 | -74.14 Mn |
| Dec 31, 2024 | -66.34 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.08 Mn |
| Dec 31, 2023 | -51.12 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.24 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.86 Mn |
| Dec 31, 2021 | -29.61 Mn |
| Sep 30, 2021 | -29.17 Mn |
| Jun 30, 2021 | -27.29 Mn |
| Mar 31, 2021 | -22.09 Mn |